Dr. Leventakos on Remaining Questions After PACIFIC Trial in Lung Cancer

Konstantinos Leventakos, MD
Published: Monday, Aug 26, 2019



Konstantinos Leventakos, MD, assistant professor of oncology, Mayo Clinic, discusses the impact of the PACIFIC trial on the stage III non–small cell lung cancer (NSCLC) treatment, as well as what questions still remain.

The PACIFIC trial showed the addition of durvalumab (Imfinzi) as consolidation therapy significantly improved progression- free survival and overall survival versus placebo in patients with stage III NSCLC who did not have disease progression after 2 or more cycles of platinum-based chemoradiation. Now, more patients with stage III NSCLC should be eligible for immunotherapy, according to Leventakos.

Remaining questions include whether immunotherapy can be administered earlier in patients with stage III NSCLC, and if so, the optimal duration of the treatment. Leventakos believes these questions will soon be answered through clinical trials.
SELECTED
LANGUAGE


Konstantinos Leventakos, MD, assistant professor of oncology, Mayo Clinic, discusses the impact of the PACIFIC trial on the stage III non–small cell lung cancer (NSCLC) treatment, as well as what questions still remain.

The PACIFIC trial showed the addition of durvalumab (Imfinzi) as consolidation therapy significantly improved progression- free survival and overall survival versus placebo in patients with stage III NSCLC who did not have disease progression after 2 or more cycles of platinum-based chemoradiation. Now, more patients with stage III NSCLC should be eligible for immunotherapy, according to Leventakos.

Remaining questions include whether immunotherapy can be administered earlier in patients with stage III NSCLC, and if so, the optimal duration of the treatment. Leventakos believes these questions will soon be answered through clinical trials.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x